Welcome to our dedicated page for TBSA news (Ticker: TBSA), a resource for investors and traders seeking the latest updates and insights on TBSA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TBSA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TBSA's position in the market.
TB SA Acquisition Corp (Nasdaq: TBSA) announced that shareholders can access its PFIC annual information statement for the fiscal year ended December 31, 2021. The report covers the taxable year beginning January 27, 2021, and concludes on December 31, 2021. Shareholders can view the statement and an accompanying investor letter through links provided in the announcement.
TB SA Acquisition Corp (NASDAQ: TBSA) received a deficiency letter from Nasdaq due to its failure to file the Quarterly Report on Form 10-Q for the period ended March 31, 2022. The company had submitted a Notification of Late Filing on May 16, 2022, but could not meet the extended deadline of May 21, 2022. TBSA plans to submit a Compliance Plan to Nasdaq within the 60-day window provided. Nonetheless, the company remains compliant with all other Nasdaq listing standards and expects to file the Form 10-Q soon, with no immediate effects on its securities listing or trading.
TB SA Acquisition Corp (Nasdaq: TBSA) received a deficiency letter from Nasdaq on
FAQ